Ubrogepant Patent Expiration

Ubrogepant is Used for the acute treatment of migraines in adults with or without aura, including those with severe hepatic or renal impairment. It was first introduced by Abbvie Inc in its drug Ubrelvy on Dec 23, 2019.


Ubrogepant Patents

Given below is the list of patents protecting Ubrogepant, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Ubrelvy US10117836 Tablet formulation for CGRP active compounds Jan 30, 2035 Abbvie
Ubrelvy US11717515 Treatment of migraine Dec 22, 2041 Abbvie
Ubrelvy US11857542 Treatment of migraine Dec 22, 2041 Abbvie
Ubrelvy US11925709 Tablet formulation for CGRP active compounds Jan 30, 2035 Abbvie
Ubrelvy US8754096 Piperidinone carboxamide azaindane CGRP receptor antagonists Jul 19, 2032 Abbvie
Ubrelvy US8912210 Piperidinone carboxamide azaindane CGRP receptor antagonists Dec 23, 2033 Abbvie
Ubrelvy US9499545 Piperidinone carboxamide azaindane CGRP receptor antagonists Nov 10, 2031 Abbvie
Ubrelvy US9833448 Piperidinone carboxamide azaindane CGRP receptor antagonists Nov 10, 2031 Abbvie


Coming Soon

Patent Strength Analyzer

Let us know if you're excited!

🤩🥱

Thank you for your response 🥳